President and Chief Executive Officer, R-PHARM US
Mark Pavao is a biopharma commercialization leader with strategic, operational, and P&L experience at companies that range from entrepreneurial ventures to big pharma. He has demonstrated success in a range of situations including US and global start-up, growth and turnaround environments. Mark has marketing, market access, sales leadership, and full lifecycle management expertise, ranging from development and launch to mid-life and patent expiry.
Prior to R-PHARM US, Mark was the President of the US Diabetes Alliance between AstraZeneca and Bristol-Myers Squibb (BMS). From 2010-2012 Mark served as President of Emerging Markets at BMS, and SVP of Global Market Access & Pricing form 2008-2012. Before moving to global roles, Mark was SVP for the Neuroscience Business Unit and VP of Plavix Marketing, both in the US Pharmaceuticals Division at BMS. Mark started at BMS as VP of Neuroscience Marketing and led the US launch of Abilify. Previously, Mark was the SVP of Sales and Marketing for NitroMed Inc. and Vice President of Sales and Marketing at Helios Health, a venture-backed healthcare information and media start-up. During his early career, Mark held progressively responsible sales, marketing, and market access positions at SmithKline Beecham.
Mark earned his MBA from The Wharton School at the University of Pennsylvania and his BA with Highest Honors in Geology from the University of North Carolina at Chapel Hill (where he was a Morehead Scholar).
Born in Amsterdam, Mark grew up as a world citizen living in Madrid, New York, Sao Paulo, and Lima. He graduated high school from St. Mark's School in Massachusetts where he was a boarding student. He is proficient in Spanish and Portuguese and continues to enjoy international travel.
President and Chief Business Officer, R-PHARM US
Demetrios Kydonieus is a senior pharmaceutical executive with proven success leading multibillion-dollar global transactions and complex negotiations. He has been instrumental in assisting small, medium and large BioPharma companies in executing their corporate strategies resulting in significant growth and shareholder value.
In 2014, Demetrios teamed up with Mark Pavao to create a differentiated specialty BioPharma company. The opportunity to work with Russia's premier pharmaceutical company, R-Pharm JSC, presented a unique opportunity to accelerate the growth and importance of the BioPharma start-up (R-PHARM US).
Prior to R-Pharm US, Demetrios was the Vice President, Strategy, Alliances and Transactions (SAT) at Bristol Myers Squibb (BMS) where he was instrumental in helping BMS implement the BioPharma transformation and execute the String of Pearls strategy.
Demetrios began working at BMS in 1998 as Director, Worldwide Regulatory Affairs in the Health Care Group. After leaving the Health Care Group, Demetrios joined the Corporate Strategy and Issues Management Group as Director, Business Risk Management, where he identified and helped manage the largest risks to the BMS strategy. Demetrios later moved with his family to Boston to be General Counsel for BMS Medical Imaging, where he was a member of the business unit's Executive Team and helped lead the divestiture of the business to private equity.
Demetrios earned his Juris Doctor degree from Quinnipiac University School of Law and his Masters of Business Administration from Duke University, Fuqua School of Business.
Vice President of Finance and Operations and Chief Financial Officer
Melissa Epperly is a healthcare investment and operating executive with extensive portfolio management experience and financial expertise. She has a proven track record of delivering sustained returns and creating shareholder value by strategically improving financing and operations as an active owner, investor and advisor.
Prior to joining R-Pharm US, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund, where she drove operational excellence in their portfolio companies and established processes to facilitate and enable exponential growth. She enhanced the value of private equity and debt investments by improving operations and serving on Boards in turnarounds. Before joining Anchorage in 2012 she was a Vice President at Goldman Sachs. She joined Goldman Sachs in 2007 as part of the leadership team that developed, built, and commercialized a novel, global equity research product for long-term investing, GS SUSTAIN, in the US and Europe.
Earlier in her career, Melissa was a management consultant with Bain & Company in New York and London, focused on international and US based pharmaceutical clients and private equity. She previously worked at Morgan Stanley in New York in healthcare investment banking and banking management, enabling pharmaceutical and biotech companies to accelerate growth through strategic M&A and capital raising.
Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
Vice President of Sales and Market Access
Richard P. Micali has extensive commercial experience in the biopharmaceutical industry in Sales, Marketing, and Market Access. This includes a variety of specialty therapeutic areas, all customer channels, P&L responsibility, and developing launch plans in big and small pharma. Throughout his career, Rich has demonstrated the ability to think strategically, successfully execute to deliver results, build teams, and develop people. He has built multiple sales teams, launched several products, and led co-promotion initiatives.
Prior to joining R-Pharm US, Rich spent the majority of his biopharma career at Bristol-Myers Squibb (BMS) where he held positions of increasing responsibility including Sales Representative, Sales Training Instructor, District Sales Manager, Senior Product Manager, Director Managed Pharmacies, Senior Director Infectious Disease Marketing, and Vice President Oncology Sales. Subsequently, Rich was Senior Vice President of Sales Services at PDI (health care commercialization company), Vice President of Sales and Market Access at Braeburn Pharmaceuticals (start up specialty company), and most recently, Vice President of Sales at Zogenix where he significantly expanded the Sales Force and launched a specialty product.
Rich holds a Bachelor of Science degree from Bowling Green State University and a MBA from John Carroll University.
Vice President, Global Supply Chain, Manufacturing and Quality
Jignesh has over 15 years of experience working in pharmaceutical, biotechnology and medical device industries. Prior to joining R-Pharm US LLC,
Jignesh has worked at Deloitte Consulting and Bristol-Myers Squibb. Jignesh has worked with supply chain organizations to develop planning organizations, streamline product planning processes, launch S&OP programs, contract manufacturing management and optimize manufacturing networks.
He also has experience in global supply chain and manufacturing network assessment, commercial business network assessment, regulatory affairs and quality management.
Jignesh has an MBA from Duke University, The Fuqua School of Business. He graduated with a Bachelor of Science in Industrial Engineering from Rutgers University.
Senior Director, Medical Affairs
Amit Patel has more than 15 years of experience in the biopharmaceutical industry with both large and small biopharma companies. He has extensive experience in both in-house and field based medical affairs and health outcomes. He has developed and executed medical affairs strategies related to medical information, medical and payor liaisons, company and investigator sponsored research, publications, medical marketing and product launches. Amit has lead medical affairs activities for the launch of nine specialty medications during his career many of which have transformed the treatment landscape in multiple therapeutic areas including interventional cardiology, system lupus erythematosus and oncology. For the past 10 years Amit has worked in the Oncology and Immunology therapeutic areas and most recently was at Merck in immuno-oncology where he supported the launch of the first PD-1 inhibitor in the US.
Amit earned his Doctorate of Pharmacy (PharmD) degree from the University of Michigan.